218 related articles for article (PubMed ID: 29350308)
1. The PPARγ agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ.
Ory V; Kietzman WB; Boeckelman J; Kallakury BV; Wellstein A; Furth PA; Riegel AT
Breast Cancer Res Treat; 2018 May; 169(1):47-57. PubMed ID: 29350308
[TBL] [Abstract][Full Text] [Related]
2. TNFAIP3 is required for FGFR1 activation-promoted proliferation and tumorigenesis of premalignant DCIS.COM human mammary epithelial cells.
Yang M; Yu X; Li X; Luo B; Yang W; Lin Y; Li D; Gan Z; Xu J; He T
Breast Cancer Res; 2018 Aug; 20(1):97. PubMed ID: 30111373
[TBL] [Abstract][Full Text] [Related]
3. The nuclear coactivator amplified in breast cancer 1 maintains tumor-initiating cells during development of ductal carcinoma in situ.
Ory V; Tassi E; Cavalli LR; Sharif GM; Saenz F; Baker T; Schmidt MO; Mueller SC; Furth PA; Wellstein A; Riegel AT
Oncogene; 2014 Jun; 33(23):3033-42. PubMed ID: 23851504
[TBL] [Abstract][Full Text] [Related]
4. Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo.
Khurana A; McKean H; Kim H; Kim SH; mcguire J; Roberts LR; Goetz MP; Shridhar V
Breast Cancer Res; 2012 Mar; 14(2):R43. PubMed ID: 22410125
[TBL] [Abstract][Full Text] [Related]
5. PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway.
Ni J; Zhou LL; Ding L; Zhao X; Cao H; Fan F; Li H; Lou R; Du Y; Dong S; Liu S; Wang Z; Ma R; Wu J; Feng J
Exp Cell Res; 2017 Dec; 361(2):246-256. PubMed ID: 29080795
[TBL] [Abstract][Full Text] [Related]
6. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
7. The PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.
Nakles RE; Kallakury BV; Furth PA
Am J Pathol; 2013 Jun; 182(6):1976-85. PubMed ID: 23664366
[TBL] [Abstract][Full Text] [Related]
8. Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer.
Lee S; Stewart S; Nagtegaal I; Luo J; Wu Y; Colditz G; Medina D; Allred DC
Cancer Res; 2012 Sep; 72(17):4574-86. PubMed ID: 22751464
[TBL] [Abstract][Full Text] [Related]
9. Everolimus Inhibits the Progression of Ductal Carcinoma
Chen G; Ding XF; Pressley K; Bouamar H; Wang B; Zheng G; Broome LE; Nazarullah A; Brenner AJ; Kaklamani V; Jatoi I; Sun LZ
Clin Cancer Res; 2020 Mar; 26(6):1486-1496. PubMed ID: 31871301
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the Transcriptome: Regulation of Cancer Stemness in Breast Ductal Carcinoma
Shan NL; Minden A; Furmanski P; Bak MJ; Cai L; Wernyj R; Sargsyan D; Cheng D; Wu R; Kuo HD; Li SN; Fang M; Maehr H; Kong AN; Suh N
Cancer Prev Res (Phila); 2020 Aug; 13(8):673-686. PubMed ID: 32467291
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of miR-223 Expression Is an Early Event during Mammary Transformation and Confers Resistance to CDK4/6 Inhibitors in Luminal Breast Cancer.
Citron F; Segatto I; Vinciguerra GLR; Musco L; Russo F; Mungo G; D'Andrea S; Mattevi MC; Perin T; Schiappacassi M; Massarut S; Marchini C; Amici A; Vecchione A; Baldassarre G; Belletti B
Cancer Res; 2020 Mar; 80(5):1064-1077. PubMed ID: 31862778
[TBL] [Abstract][Full Text] [Related]
12. Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib-resistant lung adenocarcinoma cells.
Ni J; Zhou LL; Ding L; Zhang XQ; Zhao X; Li H; Cao H; Liu S; Wang Z; Ma R; Wu J; Feng J
Cancer Med; 2018 May; 7(5):1955-1966. PubMed ID: 29573196
[TBL] [Abstract][Full Text] [Related]
13. Regulation of DCIS to invasive breast cancer progression by Singleminded-2s (SIM2s).
Scribner KC; Behbod F; Porter WW
Oncogene; 2013 May; 32(21):2631-9. PubMed ID: 22777354
[TBL] [Abstract][Full Text] [Related]
14. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
[TBL] [Abstract][Full Text] [Related]
15. Small molecule agonists of PPAR-γ exert therapeutic effects in esophageal cancer.
Sawayama H; Ishimoto T; Watanabe M; Yoshida N; Sugihara H; Kurashige J; Hirashima K; Iwatsuki M; Baba Y; Oki E; Morita M; Shiose Y; Baba H
Cancer Res; 2014 Jan; 74(2):575-85. PubMed ID: 24272485
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation.
Shah S; Brock EJ; Jackson RM; Ji K; Boerner JL; Sloane BF; Mattingly RR
Neoplasia; 2018 Sep; 20(9):951-963. PubMed ID: 30144784
[TBL] [Abstract][Full Text] [Related]
17. Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness.
Zheng ZY; Elsarraj H; Lei JT; Hong Y; Anurag M; Feng L; Kennedy H; Shen Y; Lo F; Zhao Z; Zhang B; Zhang XH; Tawfik OW; Behbod F; Chang EC
Breast Cancer Res; 2022 Oct; 24(1):68. PubMed ID: 36258226
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the transition of ductal carcinoma in situ to invasive ductal carcinoma by a Gemini vitamin D analog.
Wahler J; So JY; Kim YC; Liu F; Maehr H; Uskokovic M; Suh N
Cancer Prev Res (Phila); 2014 Jun; 7(6):617-26. PubMed ID: 24691501
[TBL] [Abstract][Full Text] [Related]
19. A Molecular Portrait of High-Grade Ductal Carcinoma In Situ.
Abba MC; Gong T; Lu Y; Lee J; Zhong Y; Lacunza E; Butti M; Takata Y; Gaddis S; Shen J; Estecio MR; Sahin AA; Aldaz CM
Cancer Res; 2015 Sep; 75(18):3980-90. PubMed ID: 26249178
[TBL] [Abstract][Full Text] [Related]
20. Mouse-INtraDuctal (MIND): an in vivo model for studying the underlying mechanisms of DCIS malignancy.
Hong Y; Limback D; Elsarraj HS; Harper H; Haines H; Hansford H; Ricci M; Kaufman C; Wedlock E; Xu M; Zhang J; May L; Cusick T; Inciardi M; Redick M; Gatewood J; Winblad O; Aripoli A; Huppe A; Balanoff C; Wagner JL; Amin AL; Larson KE; Ricci L; Tawfik O; Razek H; Meierotto RO; Madan R; Godwin AK; Thompson J; Hilsenbeck SG; Futreal A; Thompson A; Hwang ES; Fan F; Behbod F;
J Pathol; 2022 Feb; 256(2):186-201. PubMed ID: 34714554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
